Avadel Pharmaceuticals Shares RESTORE Study Results
Recent survey findings indicate that 94% of individuals diagnosed with narcolepsy prefer the once-nightly regimen of LUMRYZ over the traditional twice-nightly oxybate treatments. These results, derived from the RESTORE study, highlight meaningful improvements in nighttime experiences and overall patient satisfaction.
Insights from Patients on LUMRYZ™
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a prominent biopharmaceutical company focused on innovative treatment solutions, has released results from the RESTORE open-label study. This extensive research aimed to shed light on patient preferences regarding sodium oxybate administration. LUMRYZ, which received FDA approval in 2023, is the first once-nightly oxybate product, providing an alternative to the traditional twice-nightly treatments that have been prevalent for over twenty years.
The results, published in the journal Sleep Medicine: X, confirm that those who switched to LUMRYZ reported better sleep throughout the night, with 91% of participants noting improvements following the transition.
Challenges with Twice-Nightly Dosing
The RESTORE study revealed significant challenges associated with the twice-nightly dosing of oxybates, particularly the disruption caused by waking up for a middle-of-the-night dose. Dr. Asim Roy, a contributing investigator, noted that participants often reported feelings of grogginess and unsteadiness when they missed doses or took their medications late at night.
Key Statistics from the RESTORE Study
Among the 129 participants who transitioned from twice-nightly oxybate regimens to once-nightly LUMRYZ, several noteworthy statistics emerged:
- 69% reported missing their second oxybate dose, and 80% experienced a decline in symptom control on those days.
- More than half of those who delayed their second dose reported significant grogginess the following morning.
- 92% of participants who switched had to get out of bed for the second dose, leading to reports of falls and injuries among some individuals.
- 23% needed assistance from someone else to wake up for the middle-of-the-night dose.
Additionally, among the 98 participants who completed the patient preference questionnaire, an impressive 94% expressed a strong preference for LUMRYZ.
LUMRYZ™: A Breakthrough in Narcolepsy Treatment
As the only once-nightly treatment option available, LUMRYZ represents a significant advancement in managing narcolepsy, effectively alleviating the burden of nighttime dosing. Feedback indicates that 93% of LUMRYZ users would recommend the product to friends or family members with narcolepsy.
Understanding the Advantages of LUMRYZ™
The approval of LUMRYZ was based on the results of the pivotal Phase 3 REST-ON trial, which demonstrated significant improvements in various aspects of narcolepsy symptoms:
- Excessive daytime sleepiness (EDS).
- Overall clinician assessments of patient functionality.
- Reduction in cataplexy attacks.
With FDA endorsement, LUMRYZ not only provides a crucial option for managing narcolepsy but also comes with seven years of Orphan Drug Exclusivity, highlighting its clinical superiority over existing treatments.
Important Safety Information and Usage Guidelines
It is essential to remember that while LUMRYZ is effective, it is a prescription medication that should be used with caution. Patients are advised to avoid using it alongside other central nervous system depressants to prevent severe side effects. Misuse or abuse of the medication can lead to serious respiratory issues and other health complications. Patients should also be aware of the potential for dependence if the medication is not taken as prescribed.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals (Nasdaq: AVDL) is committed to transforming treatment options for patients with narcolepsy through innovative medications like LUMRYZ™. For more information, please contact Courtney Mogerley at (212) 698-8687 or via email.
Frequently Asked Questions
What is LUMRYZ™ used for?
LUMRYZ™ is prescribed to treat cataplexy and excessive daytime sleepiness in adults diagnosed with narcolepsy.
How does LUMRYZ™ compare to traditional oxybate treatments?
LUMRYZ™ provides a once-nightly dosing option, eliminating the need for a middle-of-the-night dose, which many patients find inconvenient.
What is the major finding from the RESTORE study?
A significant number of participants, 94%, preferred LUMRYZ over twice-nightly oxybate regimens due to enhanced nocturnal experiences and improved daily functionality.
What are the potential side effects of LUMRYZ™?
Common side effects include nausea, dizziness, and bedwetting, among others. Serious side effects may also occur, especially in cases of misuse.
How long has LUMRYZ™ been available?
LUMRYZ was approved by the FDA on May 1, 2023, as a new treatment option for narcolepsy.
